VERTEX PHARMACEUTICALS INC (VRTX)       319.98  -1.47 (-0.46%)

319.98  -1.47 (-0.46%)

US92532F1003 - Common Stock - After market: 319.99 0.01 (0%)

Buy % Consensus

77
Analysts have set a mean price target of 331.19. This target is 3.5% above the current price.
VRTX was analyzed by 35 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about VRTX.
In the previous month the buy percentage consensus was at a similar level.
VRTX was analyzed by 35 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 319.98267.65331.50331.19462.00 - -16.35% 3.60% 3.50% 44.38%

Up and Down Grades

Date Firm Action Rating
2023-01-24 Morgan Stanley Maintains Equal-Weight
2023-01-19 Piper Sandler Maintains Neutral
2023-01-18 Canaccord Genuity Initiate Hold
2023-01-17 SVB Leerink Upgrade Market Perform -> Outperform
2022-12-19 Jefferies Downgrade Buy -> Hold
2022-11-17 Argus Research Maintains Buy
2022-10-28 RBC Capital Maintains Sector Perform
2022-10-28 Barclays Maintains Overweight
2022-10-28 Wells Fargo Maintains Overweight
2022-10-28 Morgan Stanley Maintains Equal-Weight
2022-10-24 JP Morgan Maintains Overweight
2022-08-17 Piper Sandler Maintains Neutral
2022-08-08 Morgan Stanley Maintains Equal-Weight
2022-08-05 Barclays Maintains Overweight
2022-08-05 HC Wainwright & Co. Maintains Buy
2022-07-26 Piper Sandler Maintains Neutral
2022-07-13 Cantor Fitzgerald Initiate Overweight
2022-06-13 Argus Research Maintains Buy
2022-06-13 Cowen & Co. Maintains Outperform
2022-06-01 Maxim Group Upgrade Hold -> Buy
2022-05-23 SVB Leerink Initiate Market Perform
2022-05-06 Piper Sandler Maintains Neutral
2022-05-03 Morgan Stanley Upgrade Underweight -> Equal-Weight
2022-04-22 Piper Sandler Maintains Neutral
2022-02-03 RBC Capital Downgrade Outperform -> Sector Perform
2022-01-20 BMO Capital Upgrade Market Perform -> Outperform
2021-12-09 Wells Fargo Initiate Overweight
2021-12-02 RBC Capital Maintains Outperform
2021-11-19 BMO Capital Initiate Market Perform
2021-11-19 Piper Sandler Downgrade Overweight -> Neutral

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA